Rhumbline Advisers and several other firms have boosted their holdings in
Edwards Lifesciences Corporation, however, the medical device company's Q4 2025 results missed EPS forecasts, leading to a 6.2% drop. Despite experiencing margin compression to 17.5%, the company has continued its strong sales growth trajectory. Amidst strategic investments and a hiccup with
JenaValve, Edwards Lifesciences provided an upbeat 2026 guidance, reassuring investors. Several analysts have reiterated their buy ratings, while some maintain a hold stance. Notably, Wall Street has shown a bullish sentiment towards the company, even though the company reported quarterly earnings that fell short of the estimates. On the other hand,
ING Groep NV and
Machina Capital S.A.S. have reduced their stakes in the company. The price targets for Edwards Lifesciences has been raised by
Wells Fargo,
Piper Sandler, and
BTIG Research, signaling a potential renewed growth cycle despite recent setbacks.
Edwards Lifesciences Corp EW News Analytics from Fri, 25 Jul 2025 07:00:00 GMT to Fri, 13 Feb 2026 18:55:05 GMT -
Rating 6
- Innovation 7
- Information 8
- Rumor -4
